(Q38051247)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054937%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

title

The role of mammalian target of rapamycin (mTOR) inhibition in the treatment of advanced breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054937%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054937%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

Michael Gnant

series ordinal

1

1 reference

27 August 2017

publication date

1 February 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054937%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

published in

Current Oncology Reports

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054937%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054937%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054937%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

14-23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054937%20AND%20SRC:MED&resulttype=core&format=json

A 2009 update on the treatment of patients with hormone receptor-positive breast cancer

10 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

Targeted therapies for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

1st International consensus guidelines for advanced breast cancer (ABC 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

BOLERO-2 - will this change practice in advanced breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

Mechanisms of endocrine resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

"Overcoming breast cancer drug resistance with mTOR inhibitors". Could it be a myth or a real possibility in the short-term future?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

Ras, PI(3)K and mTOR signalling controls tumour cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

Somatic mutation and gain of copy number of PIK3CA in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

The PIK3CA gene is mutated with high frequency in human breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

Clinical presentation and management of mTOR inhibitor-associated stomatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

The effectiveness of commonly used mouthwashes for the prevention of chemotherapy-induced oral mucositis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

Putting evidence into practice: evidence-based interventions for the management of oral mucositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

mTOR: from growth signal integration to cancer, diabetes and ageing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0277-1

Reversing hormone resistance: have we found the golden key?

21 January 2018

1 reference

12 December 2020

HER-2-targeted therapy: lessons learned and future directions.

1 reference

12 December 2020

mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions.

1 reference

12 December 2020

Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer

1 reference

12 December 2020

Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients

1 reference

12 December 2020